Related Experiment Video
Updated: May 2, 2026
08:40
TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
Published on: June 8, 2016
13.7K
[Modern topical hemostatic agents - a breakthrough in vascular surgery]
Dariusz Janczak1, Artur Ruciński2, Zuzanna Rucińska2
1Zakład Specjalności Zabiegowych, Katedra Pielęgniarstwa Klinicznego Uniwersytetu Medycznego im. Piastów Śląskich we Wrocławiu, Wrocław, Polska.
Polimery W Medycynie
|March 6, 2014
Summary
Topical hemostatic agents like PerClot®, Fibrillar®, and Surgiflo® significantly reduce blood loss and shorten operation times in vascular surgery. This improves patient safety during arterial anastomoses.
Area of Science:
- Vascular Surgery
- Surgical Hemostasis
- Biomaterials
Context:
- Difficulties in controlling bleeding during arterial anastomoses are a common surgical challenge.
- Topical hemostatic agents offer a potential solution for managing intraoperative hemorrhage.
- This study evaluates three specific agents: PerClot®, Fibrillar®, and Surgiflo®.
Purpose:
- To assess the impact of topical hemostatic agents on blood loss and operation time.
- To compare the efficacy of PerClot®, Fibrillar®, and Surgiflo® in arterial anastomoses.
- To evaluate their use in both primary anastomoses and those involving synthetic grafts.
Summary:
- A study involving 106 patients in Wroclaw utilized PerClot® (26), Fibrillar® (65), and Surgiflo® (15) to manage bleeding during vascular procedures.
- These agents were applied when difficulties arose in achieving hemostasis.
- The agents demonstrated effectiveness in controlling bleeding in 95% of cases.
Impact:
- Topical hemostatic agents significantly reduced blood loss in 95% of patients.
- Operation times were shortened in 95% of cases, indicating increased surgical efficiency.
- The observed decrease in blood loss and operative duration contributes to enhanced patient safety.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:05Introduction to Hemostasis
14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K